COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00707980




Registration number
NCT00707980
Ethics application status
Date submitted
27/06/2008
Date registered
2/07/2008
Date last updated
13/12/2013

Titles & IDs
Public title
Safety and Tolerability of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder
Scientific title
A Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 in Subjects With Major Depressive Disorder
Secondary ID [1] 0 0
2008-001581-91
Secondary ID [2] 0 0
LuAA21004_301
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Major Depressive Disorder 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Depression

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Vortioxetine

Experimental: Vortioxetine - Vortioxetine 2.5 mg, 5 mg or 10 mg, encapsulated tablets, orally, once daily for up to 52 weeks. For the first week of treatment all participants received 5 mg/day vortioxetine, thereafter, the dose could be increased to 10 mg/day or decreased to 2.5 mg/day, based on participant's response and tolerability as judged by the investigator.


Treatment: Drugs: Vortioxetine
Encapsulated vortioxetine immediate-release tablets

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Physical Examination Findings - Physical examination consisted of the following body systems: (1) appearance; (2) extremities; (3) skin; (4) head and neck; (5) eyes, ears, nose, and throat; (6) lungs and chest; (7) heart and cardiovascular system; (8) abdomen; and (9) musculoskeletal system. An assessment of the nervous system was conducted; any findings were captured under the appropriate body area.
Each system was assessed as normal or abnormal.
Timepoint [1] 0 0
Baseline and Week 52
Primary outcome [2] 0 0
Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings - Participants with at least one post-baseline potentially clinically significant (as defined in the table below) serum chemistry, hematology or urinalysis result. ULN = upper limit of normal; LLN = Lower limit of normal.
Timepoint [2] 0 0
Weeks 4, 8, 12, 20, 28, 36, 44 and 52
Primary outcome [3] 0 0
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings - A standard 12-lead ECG was performed at the designated study visits. The central reader reviewed and recorded the intervals (PR, QRS, RR, QT, and corrected QT interval [QTc]), and interpreted the ECG using 1 of the following categories: within normal limits or abnormal. The number of participants with at least one post-baseline potentially clinically significant ECG finding is reported. bpm = beats per minute; QTcB = QT interval corrected using Bazett's formula; QTcF = QT interval corrected using Fridericia's formula.
Timepoint [3] 0 0
Weeks 4, 12, 24, 36 and 52
Primary outcome [4] 0 0
Number of Participants With Adverse Events (AEs) - The intensity (severity) of each AE was defined as:
Mild: caused minimal discomfort and did not interfere in a significant manner with normal activities.
Moderate: sufficiently uncomfortable to produce some impairment of normal activities.
Severe: incapacitating, preventing the patient from participating in normal activities.
The causal relationship between an AE and study drug was assessed by the investigator as Probable, Possible or Not Related; Related=AEs with causality of Possibly or Probably. A serious AE (SAE) was defined as any untoward medical occurrence that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, led to a congenital anomaly/birth defect, or was an important medical event that either jeopardized the patient, required intervention to prevent any of the SAEs defined above, a suicide attempt or an abortion.
Timepoint [4] 0 0
From the first dose of open-label study drug until 4 weeks after the last dose (up to 56 weeks)
Primary outcome [5] 0 0
Number of Participants With Potentially Clinically Significant Vital Sign Findings - Participants with at least one potentially clinically significant post-baseline vital sign finding. The definition of clinically significant is included in the table below for each parameter. SSBP = supine systolic blood pressure; SDBP = supine diastolic blood pressure.
Timepoint [5] 0 0
Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44 and 52
Secondary outcome [1] 0 0
Change From Baseline in Hamilton Depression Scale-24 Item (HAM-D24) Total Score - The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
Timepoint [1] 0 0
Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44 and 52.
Secondary outcome [2] 0 0
Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score - The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
Timepoint [2] 0 0
Baseline and Weeks 4, 24 and 52
Secondary outcome [3] 0 0
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score - The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
Timepoint [3] 0 0
Baseline and Weeks 4, 24 and 52
Secondary outcome [4] 0 0
Change From Baseline in the Clinical Global Impression of Severity of Illness Scale - The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. Final Visit includes data from Week 52 or earlier for participants who didn't complete the 52 weeks.
Timepoint [4] 0 0
Baseline and Weeks 4, 24 and 52
Secondary outcome [5] 0 0
Change From Baseline to the Final Visit in 36-item Short-form Health Survey (SF-36) - The Medical Outcomes Study SF-36 is a participant self-rated questionnaire that is a general measure of perceived health status comprising 36 questions, which yields an 8-scale health profile. The 8 health concepts are: 1. Limitation in physical activities because of health problems. 2. Limitations in usual role activities because of physical health problems. 3. Bodily pain. 4. Limitations in social activities because of physical or emotional problems. 5. General mental health (psychological distress and well-being). 6. Limitations in usual role activities because of emotional problems. 7. Vitality (energy and fatigue). 8. General health perception. Each scale ranges from 0 (best) - 100 (worst).
Timepoint [5] 0 0
Baseline and Week 52
Secondary outcome [6] 0 0
Change From Baseline to the Final Visit in the Sheehan Disability Scale - The Sheehan Disability Scale (SDS) assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.
Timepoint [6] 0 0
Baseline and Week 52
Secondary outcome [7] 0 0
Health Care Resource Utilization Assessed by the Health Economic Assessment Questionnaire - Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.
Timepoint [7] 0 0
Baseline and Week 52

Eligibility
Key inclusion criteria
- Has completed the double blind treatment period of either study Lu AA21004_304
(NCT00672620) or LuAA21004_305 (NCT00735709) immediately prior to enrollment in the
extension study (ie, the baseline visit is the same visit as the completion visit of
the double blind treatment of the preceding protocol).

- Suffers from a major depressive episode as the primary diagnosis according to
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision
(DSM-IV-TR) criteria (classification code 296.xx) at entry into the prior Lu
AA21004_304 or Lu AA21004_305 study.
Minimum age
18 Years
Maximum age
76 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- In addition to meeting the exclusion criteria for studies Lu AA21004_304 or Lu
AA21004_305 at the time of enrollment into those studies respectively, with the
exception of the criteria prohibiting previous exposure to Lu AA21004 and
investigational drugs, and the criteria prohibiting patients with increased
intraocular pressure, or risk of acute narrow-angle glaucoma, the following exclusion
criteria apply:

- Has Major Depressive Disorder for whom other psychiatric disorders (mania,
bipolar disorder, schizophrenia, or any psychotic disorder) have been diagnosed
during the prior study.

- The participant, in the investigator's opinion, has a significant risk of suicide
and/or a score of =5 points on item 10 (suicidal thoughts) of the Montgomery
Åsberg Depression Rating Scale.

- The participant, in the opinion of the investigator, is unlikely to comply with
the clinical study protocol or is unsuitable for any reason.

- Has a clinically significant moderate or severe ongoing adverse event related to
study medication from the prior study.

- Has used/uses disallowed concomitant medication.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Elizabeth Vale
Recruitment hospital [2] 0 0
- Richmond
Recruitment hospital [3] 0 0
- Southport
Recruitment postcode(s) [1] 0 0
- Elizabeth Vale
Recruitment postcode(s) [2] 0 0
- Richmond
Recruitment postcode(s) [3] 0 0
- Southport
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Kansas
Country [6] 0 0
United States of America
State/province [6] 0 0
Kentucky
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Mississippi
Country [10] 0 0
United States of America
State/province [10] 0 0
New York
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Oklahoma
Country [13] 0 0
United States of America
State/province [13] 0 0
Pennsylvania
Country [14] 0 0
United States of America
State/province [14] 0 0
Tennessee
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Utah
Country [17] 0 0
United States of America
State/province [17] 0 0
Washington
Country [18] 0 0
United States of America
State/province [18] 0 0
Wisconsin
Country [19] 0 0
Croatia
State/province [19] 0 0
Osijek
Country [20] 0 0
Croatia
State/province [20] 0 0
Zagreb
Country [21] 0 0
France
State/province [21] 0 0
Bully les Mines
Country [22] 0 0
France
State/province [22] 0 0
Marseille
Country [23] 0 0
France
State/province [23] 0 0
Strasbourg
Country [24] 0 0
Germany
State/province [24] 0 0
Berlin
Country [25] 0 0
Germany
State/province [25] 0 0
Bochum
Country [26] 0 0
Germany
State/province [26] 0 0
Chemnitz
Country [27] 0 0
Germany
State/province [27] 0 0
Huettenberg
Country [28] 0 0
Germany
State/province [28] 0 0
Leipzig
Country [29] 0 0
Germany
State/province [29] 0 0
München
Country [30] 0 0
Germany
State/province [30] 0 0
Nuernberg
Country [31] 0 0
Germany
State/province [31] 0 0
Wiesbaden
Country [32] 0 0
Korea, Republic of
State/province [32] 0 0
Buchon
Country [33] 0 0
Korea, Republic of
State/province [33] 0 0
Gyeonggi-do
Country [34] 0 0
Korea, Republic of
State/province [34] 0 0
Incheon
Country [35] 0 0
Korea, Republic of
State/province [35] 0 0
Seoul
Country [36] 0 0
Latvia
State/province [36] 0 0
Liepaja
Country [37] 0 0
Latvia
State/province [37] 0 0
Riga
Country [38] 0 0
Latvia
State/province [38] 0 0
Sigulda
Country [39] 0 0
Lithuania
State/province [39] 0 0
Siauliai
Country [40] 0 0
Lithuania
State/province [40] 0 0
Vilnius
Country [41] 0 0
Malaysia
State/province [41] 0 0
Kuala Lumpur
Country [42] 0 0
Netherlands
State/province [42] 0 0
SchHoogfliet
Country [43] 0 0
Netherlands
State/province [43] 0 0
Wildervank
Country [44] 0 0
Netherlands
State/province [44] 0 0
Zwijndrecht
Country [45] 0 0
Poland
State/province [45] 0 0
Bialystok
Country [46] 0 0
Poland
State/province [46] 0 0
Leszno
Country [47] 0 0
Poland
State/province [47] 0 0
Pruszków
Country [48] 0 0
Poland
State/province [48] 0 0
Skórzewo
Country [49] 0 0
Poland
State/province [49] 0 0
Torun
Country [50] 0 0
Poland
State/province [50] 0 0
Tuszyn
Country [51] 0 0
Russian Federation
State/province [51] 0 0
Moscow
Country [52] 0 0
Russian Federation
State/province [52] 0 0
Nizhny Novgorod
Country [53] 0 0
Russian Federation
State/province [53] 0 0
Novosibirsk
Country [54] 0 0
Russian Federation
State/province [54] 0 0
Omsk
Country [55] 0 0
Russian Federation
State/province [55] 0 0
St. Petersburg
Country [56] 0 0
Russian Federation
State/province [56] 0 0
Stavropol
Country [57] 0 0
Russian Federation
State/province [57] 0 0
Tomsk
Country [58] 0 0
Serbia
State/province [58] 0 0
Belgrade
Country [59] 0 0
South Africa
State/province [59] 0 0
Bryanston
Country [60] 0 0
South Africa
State/province [60] 0 0
Durban
Country [61] 0 0
South Africa
State/province [61] 0 0
Lyttelton
Country [62] 0 0
South Africa
State/province [62] 0 0
NoordHeuwel
Country [63] 0 0
South Africa
State/province [63] 0 0
Pretoria
Country [64] 0 0
Taiwan
State/province [64] 0 0
Kaohsiung
Country [65] 0 0
Ukraine
State/province [65] 0 0
Dnepropetrovsk
Country [66] 0 0
Ukraine
State/province [66] 0 0
Kiev
Country [67] 0 0
Ukraine
State/province [67] 0 0
Lugansk
Country [68] 0 0
Ukraine
State/province [68] 0 0
Simferopol
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Glasgow

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Takeda
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
H. Lundbeck A/S
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine the long-term efficacy and safety of vortioxetine,
once daily (QD), in adults with major depressive disorder.
Trial website
https://clinicaltrials.gov/show/NCT00707980
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director, Clinical Science
Address 0 0
Takeda
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications